help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Libanati, C.
Right arrow Articles by Mohan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Libanati, C.
Right arrow Articles by Mohan, S.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 8 2807-2814
Copyright © 1999 by The Endocrine Society


Original Studies

Studies on the Potential Mediators of Skeletal Changes Occurring during Puberty in Girls1

Cesar Libanati, David J. Baylink, Eliana Lois-Wenzel, Narasimhan Srinivasan and Subburaman Mohan

Departments of Medicine, Pediatrics, Biochemistry and Physiology, Loma Linda University and Musculoskeletal Disease Center, J. L. P. Memorial Veterans Administration Medical Center (C.L., D.J.B., S.M.); and the Department of Pediatrics, Loma Linda University (E.L.-W.), Loma Linda, California 92357; and the Department of Endocrinology, University of Madras (N.S.), Taramani, Madras 600 113, India

Address all correspondence and requests for reprints to: Dr. Subburaman Mohan, Research Service (151), J. L. P. Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, California 92357. E-mail: hyperlink mailto:mohans{at}llvamc.va.gov


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
In this study we evaluated the role of cytokines and insulin-like growth factor (IGF) system in mediating the skeletal changes that occur during puberty by determining the relationship between serum levels of cytokines and IGF system components vs. 1) bone formation and resorption parameters in serum and urine, 2) bone density, and 3) metacarpal bone indexes in 65 pubertal girls. Lumbar bone mineral density and metacarpal width increased significantly both between Tanner stages (TS) II and III and between TS III and IV, whereas metacarpal length and serum levels of stimulatory IGF system components increased significantly only between TS II and III. Biochemical markers of bone turnover were significantly less in TS IV girls than in TS II and III girls. In general, serum levels of IGF system components showed a significant positive correlation to bone density in TS II and III girls, whereas bone resorption markers corrected for creatinine showed a significant negative correlation to bone density in TS III and IV girls. Serum levels of IGF system components showed a significant positive correlation to serum osteocalcin levels as well as metacarpal width in TS II girls, whereas urinary levels of bone resorption markers showed a significant negative correlation to metacarpal width in TS IV girls. Serum levels of interleukin-6 were decreased during late puberty and were negatively correlated with bone density in TS III and IV girls. Our data are consistent with a model in which the sex steroid hormone-induced increase in the IGF system leads to an increase in longitudinal growth and periosteal bone expansion, whereas the sex steroid hormone-induced reduction in bone turnover (possibly via cytokines) leads to an increase in cortical thickness via endosteal regulation.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
OSTEOPOROSIS is a disease characterized by low bone mineral density (BMD) leading to increased bone fragility, with fractures occurring even after minimal trauma (1, 2). As bone density is one of the main determinants of fracture risk, maximizing BMD at skeletal maturity (peak bone mass) is a logical strategy to protect against osteoporosis. It is well known that the rate of bone accretion increases dramatically during puberty and is a function of pubertal stage, rather than chronological age (3, 4, 5, 6). As relatively small differences in bone mass and BMD at maturity of 5–10% could contribute to substantial differences in the incidence of subsequent osteoporotic fractures (7, 8), it is of great importance to understand the molecular mechanisms that contribute to the rapid changes in BMD that occur during puberty.

The dramatic accumulation of bone mass during puberty is caused by changes in both modeling and remodeling that occur simultaneously during this period of life. In addition, there is some suggestion that both enhanced bone formation and decreased bone resorption contribute to the increment in bone density that occurs during puberty. With respect to bone resorption, recent studies by Slemenda et al. (9) and our group (10) have provided evidence that reduced rates of skeletal modeling during periods of growth could contribute to the bone density increase seen during puberty. However, the mechanisms that contribute to reduced remodeling during puberty remain poorly understood. In this study we evaluated the role of serum cytokines in mediating the changes in bone resorption that occur during puberty based on accumulated evidence that cytokines are important regulators of bone resorption in vitro and in vivo and that sex steroids (which increase during puberty) inhibit the production of one or more cytokines (11, 12, 13).

Turning to the potential role of bone formation in the acquisition of peak bone density, it has been suggested that molecules that might signal such an increase in bone formation would include the GH-insulin-like growth factor (IGF) axis. This concept is based on the well known finding that GH production is increased during sexual development and that the effects of GH on skeletal growth are largely mediated via IGF-I (14, 15, 16). The findings that bone formation is impaired severely in GH-deficient and IGF knockout mice and that exogenous administration of IGFs stimulates bone formation parameters in both animals and humans (17, 18, 19) further stress the important role for the IGF system in regulating bone formation. It is also known that the actions of IGFs in bone are regulated by complex interplay between inhibitory and stimulatory IGF-binding proteins (IGFBPs) and their corresponding proteases (20, 21).

The purposes of this study were 2-fold. Firstly, we evaluated whether the skeletal accretion that occurs during puberty is due to increased bone formation and/or decreased bone resorption by determining the relationship between biochemical indexes of bone turnover vs. 1) bone mineral content (BMC) adjusted for body mass index (BMI), and 2) metacarpal bone indexes. Secondly, we evaluated the role of cytokines and IGF system components in mediating the skeletal changes that occur during puberty by determining the relationship between serum levels of cytokines and stimulatory IGF system components vs. 1) bone formation and resorption parameters, 2) BMC adjusted for BMI, and 3) metacarpal bone indexes.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Subjects

This study was approved by the institutional review board of our institution. Eighty-one Caucasian girls (age range, 9.4–14.8 yr old) were recruited from the community. Each girl and parent signed an informed consent form. Sixteen girls were not eligible [bone age different than chronological age (n = 2), or did not complete the blood draw or the 24-h urine collection (n = 14)]. All remaining 65 girls (age range, 9.4–14.4 yr old) were in good health, free of medical problems, and not taking any medications and had a bone age, as determined by hand x-ray, within 1 yr of the chronological age. The girls were grouped according to sexual development into Tanner stage (TS) II (n = 19), TS III (n = 24), or TS IV (n = 22). Height and weight were measured using a stadiometer and a calibrated scale, respectively. Demographic data for the entire group and for each TS of sexual development are detailed in Table 1Go.


View this table:
[in this window]
[in a new window]
 
Table 1. Demographic data for study subjects

 
Metacarpal indexes

Standardized right hand x-rays were obtained to determine bone age, according to the standardized atlas of Greulich and Pyle (22). Skeletal changes during puberty were followed by measurement of metacarpal changes established by the pioneering work of Garn et al. (23). In addition, the x-rays were used to measure, using a caliper, the following metacarpal indexes at the middle of the second metacarpal: metacarpal length, total metacarpal thickness (tt), and cortical thickness (ct). Marrow width (mw) was determined by the formula: mw = tt - 2 x ct. Metacarpal indexes were obtained in duplicate by two different observers. The coefficient of variation for metacarpal measurements was less than 2%.

BMD and BMC measurements

Lumbar BMD and BMC measurements were performed at the L1–L4 region using a QDR 1000 (Hologic, Inc., Waltham, MA). Because of differences in bone sizes between girls at different TS, we also adjusted BMC measurements for BMI and calculated bone mineral apparent density (BMAD) according to the method of Katzman et al. (24).

Serum and urine samples

Blood samples were obtained by arm venipuncture between 0800–0900 h. After clotting and centrifugation, serum was separated and aliquoted into 250-µL samples. Serum samples were stored at -70 C until assay time. To reduce interassay variation, all samples were run in the same assay. Twenty-four-hour urine collections were obtained on a hydroxyproline-free diet. Urine volumes were measured, and aliquots of urine were frozen at -20 C until assay time.

Bone turnover assays

Bone formation was assessed by serum skeletal alkaline phosphatase (ALP) and serum osteocalcin as described previously (25, 26). Bone resorption was assessed by urinary hydroxyproline (OH-Prol), pyridinoline (Pyr), and deoxypyridinoline (Dpyr) measurements (25, 26). Urinary creatinine was measured by standard methods.

IGF system components

Serum levels of IGF-I and IGF-II were measured after complete removal of IGFBPs by the rapid acid gel filtration protocol as previously described (27). IGF-I and IGF-II levels were measured by RIA using recombinant human IGF-I and IGF-II standard and tracer. The intra- and interassay coefficients of variation were less than 10% for both of these assays. The cross-reactivity of IGF-II in the IGF-I assay was less than 0.1%, whereas the cross-reactivity of IGF-I in the IGF-II assay was less than 0.5%. IGFBP-3 levels in the serum were measured by RIA using rabbit polyclonal antiserum and recombinant IGFBP-3 as standard and tracer, respectively (28). IGFBP-5 levels were measured using polyclonal guinea pig antiserum and recombinant IGFBP-5 as standard and tracer, respectively (29). Other IGFBPs did not show significant cross-reactivity in either of these two assays. The intra- and interassay coefficients of variation for IGFBP-3 and IGFBP-5 measurements were less than 10%.

Sex steroid hormones

The serum estradiol level was measured by RIA (ICN Biomedicals, Inc. Costa Mesa, CA). Serum free testosterone was determined by coated tube RIA (Diagnostics Systems Laboratories, Inc., Webster, TX). The intraassay coefficient of variation was less than 5% for both assays. Lower limits of detection for serum estradiol and serum free testosterone were 10 and 0.05 pg/mL, respectively.

Cytokines

Serum levels of interleukin-1ß (IL-1ß), IL-6, IL-11, macrophage colony-stimulating factor, and tumor necrosis factor-{alpha} were measured by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN).

Statistics

Regression analyses, multiple step regression analyses, t test, and one-way ANOVA were performed using Systat 5.03 for Windows (Systat, Inc., Evanston, IL). Results are given as the mean ± SEM. P < 0.05 was considered significant.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Relationship between sexual development and skeletal changes

Skeletal changes were evaluated by changes in lumbar BMD and lumbar BMC content as well as by changes in metacarpal bone indexes in girls at TS II, III, and IV. Lumbar BMD and BMC increased by 19% (P < 0.001) and 45% (P < 0.001), respectively, between TS II and III and by 18% (P < 0.001) and 28% (P < 0.001) between TS III and IV (Table 2Go). Between TS II and IV, BMD was increased by 40%, and BMC was increased by 87%. The increase in BMC could not be attributed to the increase in body size alone, as BMC was adjusted for BMI, and BMAD also increased significantly between TS II and IV (Table 2Go). Metacarpal length increased significantly between TS II and III, but not between TS III and IV (Fig. 1Go). In contrast, metacarpal width increased significantly between TS II and III as well as between TS III and IV. Marrow width, on the other hand, decreased significantly in TS IV girls compared to that in TS III girls (Fig. 1Go).


View this table:
[in this window]
[in a new window]
 
Table 2. Changes in lumbar BMD, BMC, BMC/BMI, and BMAD in girls in Tanner stages (TS) II, III, and IV

 


View larger version (24K):
[in this window]
[in a new window]
 
Figure 1. Changes in metacarpal length (A), total thickness (B), and marrow width (C) in girls during sexual development. Values are the mean ± SEM. a, P < 0.05 vs. TS II; b, P < 0.05 vs. TS III.

 
Relationship between sexual development and markers of bone turnover

Serum levels of skeletal ALP and osteocalcin showed no significant changes between TS II and III. Serum levels of skeletal ALP were significantly reduced (27%) in TS IV girls compared to those in TS II and III girls. The serum osteocalcin level was also 18% less in TS IV girls than in TS II girls; however, this difference did not reach statistical significance (Table 3Go). Urinary levels of bone resorption markers (OH-Prol, Pyr, and Dpyr) were significantly less in TS IV girls than in TS II and III girls, but were not different between TS II and III girls, presumably due to the small sample size (Table 3Go). OH-Prol and Pyr markers were modestly correlated (r = 0.40; P < 0.05), whereas Pyr and Dpyr urinary markers were highly correlated (r = 0.92; P < 0.001). Urinary creatinine levels (24 h) were not significantly different in girls between TS (data not shown).


View this table:
[in this window]
[in a new window]
 
Table 3. Changes in markers of bone turnover in girls belonging to Tanner stages (TS) II, III, and IV

 
Relationship between changes in BMD and BMC vs. markers of bone turnover during sexual development

Bone formation markers did not correlate with BMD, BMC, BMAD, or BMC adjusted for BMI. In contrast, bone resorption markers adjusted for creatinine showed a significant negative correlation to BMD, BMC/BMI, as well as BMAD for all subjects combined and for girls in TS III and IV, when changes in bone resorption take place (Table 4Go). Furthermore, those subjects in the top tertile of BMC had significantly lower OH-Prol, Pyr, and Dpyr (P < 0.05) compared to those in the lower tertile (data not shown). Using bone resorption values unadjusted for creatinine reduced the significance of the correlations between BMD and bone resorption markers.


View this table:
[in this window]
[in a new window]
 
Table 4. Correlations between bone resorption markers vs. skeletal changes in TS III and IV girls

 
Relationship between metacarpal bone indexes and markers of bone turnover during sexual development

Neither osteocalcin nor skeletal ALP were correlated with metacarpal indexes, except during TS II, when cortical and total thickness were positively correlated with osteocalcin (r = 0.64 and 0.74, respectively; P < 0.01). On the other hand, bone resorption was negatively associated with cortical thickness (r = -0.40, -0.50, and -0.49, respectively, for OH-Prol, Pyr, and Dpyr; all P < 0.01) and positively associated with marrow width (r = 0.34, 0.29, and 0.29 for OH-Prol, Pyr, and Dpyr, respectively; all P < 0.05) in the combined data from all three TS. Table 4Go shows the correlations between bone resorption markers and skeletal changes in the pooled data from TS III and IV girls during the phase when active resorption was taking place.

Relationship between sexual development and IGF system components

Serum levels of IGF-I and IGF-II were 50% and 14% higher, respectively, in TS III girls than in TS II girls (P < 0.001). Serum levels of IGFBP-3 and IGFBP-5 were also significantly higher in TS III girls than in TS II girls (Fig. 2Go). None of the stimulatory IGF system components was significantly different between TS III and TS IV girls. Between TS II and IV of sexual development, age was positively associated with IGF-I, IGFBP-3, and IGFBP-5 (r = 0.50, 0.32, and 0.40, respectively; all P < 0.01), but not IGF-II (r = -0.07; P = NS).



View larger version (24K):
[in this window]
[in a new window]
 
Figure 2. Changes in serum levels of IGF-I (A), IGF-II (B), IGFBP-3 (C), and IGFBP-5 (D) in girls during sexual development. Values are the mean ± SEM. a, P < 0.05 vs. TS II.

 
Relationship between serum IGF system components and BMD and BMC during sexual development

Table 5Go shows the correlation between serum IGF system components and BMC adjusted for BMI in TS II, III, and IV girls. In the pooled data from TS II and III girls, serum levels of IGF-I, IGFBP-3, and IGFBP-5, but not IGF-II, showed a significant positive correlation to BMC adjusted for BMI. In general, serum levels of IGF system components showed a significant positive correlation to BMC adjusted for BMI in TS II and III girls, but not in TS IV girls. Similar correlations were obtained between serum levels of IGF-I, IGFBP-3, and IGFBP-5 vs. BMD, BMC, or BMAD (data not shown).


View this table:
[in this window]
[in a new window]
 
Table 5. Correlation between serum IGF system components and BMC adjusted for BMI in girls belonging to Tanner stages II, III, and IV

 
Relationship between serum IGF components and metacarpal indexes

For all subjects combined, IGF-I, IGFBP-3, and IGFBP-5 were significantly correlated to cortical thickness (r = 0.60, 0.45, and 0.52, respectively; all P < 0.001), total thickness (r = 0.66, 0.55, and 0.56, respectively; all P < 0.001), and metacarpal length (r = 0.39, 0.36, and 0.34, respectively; all P < 0.01), but not with marrow width (r = -0.10,0.02 and -0.11, respectively; P = NS). IGF-II did not correlate with any metacarpal index value. Within each TS of sexual development, only cortical and total metacarpal thickness correlated significantly with IGF-I, IGFBP-3, and IGFBP-5. Those associations were strongest during TS II and were lost with advancing sexual development (Fig. 3Go and Table 6Go). Serum levels of IGF-I, IGFBP-3, and IGFBP-5 showed significant positive correlations to metacarpal bone length in TS II, but not in TS IV, girls (data not shown). The correlations between serum levels of IGF-I vs. metacarpal bone length and width in TS II girls are plotted in Fig. 3Go.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 3. Correlation between serum levels of IGF-I vs. metacarpal length (A), metacarpal width (B), and serum osteocalcin (C) levels in girls at Tanner stage II.

 

View this table:
[in this window]
[in a new window]
 
Table 6. Correlation between serum IGF system components and metacarpal bone indexes in girls belonging to Tanner stages (TS) II, III, and IV

 
Relationship between serum IGF system components and markers of bone turnover during sexual development

Serum levels of IGF-I showed a significant positive correlation to serum osteocalcin levels (r = 0.76; P < 0.001; Fig. 3Go) in TS II, but not in TS IV (r = -0.02), girls. Similarly, serum levels of IGFBP-3 (r = 0.67; P < 0.01) and IGFBP-5 (r = 0.40; P < 0.01) showed a significant positive correlations to serum osteocalcin levels in TS II, but not in TS IV, girls. None of the serum IGF system components measured showed a significant correlation with bone resorption markers in the pooled data or in individual TS.

Relationship between serum levels of cytokines and bone density vs. urinary bone resorption markers

Because BMC and BMC/BMI were negatively correlated with bone resorption (r = -0.86; P < 0.001) and because cytokines have been shown to be important regulators of osteoclastic bone resorption, we tested the hypothesis that the inhibition of bone resorption during sexual development was mediated by changes in serum cytokine levels. Of the serum levels of various cytokines tested (IL-1ß, IL-6, IL-11, macrophage colony-stimulating factor, and tumor necrosis factor-{alpha}), only serum levels of IL-6 decreased during late puberty and were negatively correlated to BMC/BMI during TS III and IV (r = 0.45; P = 0.02 and r = 0.37; P < 0.05, respectively).

Relationship between metacarpal indexes and sexual hormones

Because sex steroid hormones have been shown to play a major role in the regulation of bone turnover, we determined the relationship between metacarpal indexes and sex steroid hormone levels. As expected, both serum free testosterone and serum estradiol increased between TS II and IV (Table 7Go). Estradiol was not correlated to any metacarpal index. On the other hand, serum free testosterone was positively correlated to cortical thickness (r = 0.37; P < 0.05) and to total thickness (r = 0.33; P < 0.05).


View this table:
[in this window]
[in a new window]
 
Table 7. Changes in serum levels of estradiol, testosterone, and IL-6 in girls belonging to Tanner stages (TS) II, III, and IV

 
Multiple regression analysis revealed independent significant correlations between cortical thickness and IGF system components as well as between cortical thickness and serum-free testosterone. When girls in TS II and III were grouped, cortical thickness showed the strongest association with the IGF system (r = 0.67; P < 0.001). When girls in TS III and IV were grouped, cortical thickness showed the strongest association with serum free testosterone (r = 0.43; P < 0.05).


    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Puberty provides a unique window in time to evaluate the potential mechanisms responsible for changes in bone density, as large increases in bone density are known to occur during sexual development. The findings of this study are consistent with the recent demonstration in our laboratory and other laboratories that a decrease in bone turnover is an important mechanism contributing to the rapid increase in bone density that occurs during puberty (9, 10, 30, 31). In addition, our findings support the hypothesis advanced by the pioneering observations of Garn et al. (23) that the puberty-induced gain in bone density is in part due to an increase in periosteal apposition, as reflected by the metacarpal measurements. Our data further advance the important role for the stimulatory IGF system in mediating skeletal growth as well as effecting positive changes in the bone remodeling balance seen during puberty.

The rapid accretion of bone during the period of sexual maturation is associated with changes in both longitudinal bone growth as well as cortical thickness. Our findings demonstrate that increases in metacarpal bone length ceased to occur after TS III, whereas the increase in cortical thickness continued to occur beyond TS III. These data suggest that different mechanisms may regulate increases in longitudinal bone growth vs. cortical thickness, both of which occur during the puberty-induced growth spurt and both of which potentially relate to fracture risk later in life. In terms of potential signaling molecules that contribute to the rapid increase in longitudinal bone growth, the GH-IGF axis is a potential candidate based on a number of observations (14, 15, 17, 18, 19, 32, 33, 34). The positive association between increasing serum levels of IGF stimulatory system components and metacarpal bone length as well as serum IGF-I and osteocalcin levels in TS II girls, but not in TS IV girls, is consistent with the idea that up-regulation of IGF-I and its stimulatory binding proteins could in part contribute to the longitudinal bone growth that occurs during puberty.

In addition to the longitudinal growth spurt associated with puberty, we have confirmed the work of others that cortical thickness also increases during sexual development. In this regard, the increase in cortical width during puberty may relate to an increase in periosteal bone formation, a decrease in endosteal bone resorption, or both. The finding of our study that the cortical thickness of metacarpal bone increases significantly between TS II and III without a corresponding decrease in either marrow width or the rate of bone resorption is consistent with the idea that an increase in periosteal bone formation could in part contribute to the observed differences in cortical thickness during early pubertal changes. The finding that serum osteocalcin levels showed a significant positive correlation with cortical thickness in TS II girls (r = 0.66; P < 0.001) is consistent with the above hypothesis. The increase in periosteal bone formation may be mediated in part by the rapid increase in the production of stimulatory IGF system components that occur during the same time period based on the findings in this study (Fig. 4Go) as well as other studies (35, 36, 37, 38). If the IGF-induced increase in bone formation contributes in part to the changes in cortical width that occur between TS II and III, we would anticipate higher serum levels of bone formation markers in girls at TS III than in those at TS II. However, the mean serum osteocalcin and ALP (skeletal isoenzyme) levels were essentially unchanged between TS II and III girls in our study. The likely explanation for this apparent discrepancy is that complex changes (i.e. longitudinal growth, periosteal expansion, modeling-dependent remodeling, and sex hormone-dependent reduction in remodeling of trabecular bone) are occurring in the skeleton during puberty and that contemporary bone turnover markers cannot discern the various processes occurring at the same time.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 4. Schematic representation of changes in metacarpal bone width during sexual development. A cross-section of metacarpal bone is shown. The increase in metacarpal bone width between TS II and III appears to be caused primarily by periosteal envelope expansion, which may in part be mediated by up-regulation of the GH-IGF axis. Between TS III and IV, both total width and cortical width increase. The increase in total width is primarily associated with an up-regulation of testosterone in addition to the IGF action. The significant decrease in marrow width during this period may be caused primarily by a reduction of endosteal bone resorption, which may be mediated in part by a sex steroid-induced decrease in the production of IL-6 as well as other cytokines.

 
Cortical thickness, however, continued to increase beyond TS III in contrast to metacarpal bone length, which ceased to increase after TS III. Our study suggests that the increase in cortical thickness between TS III and IV appears to have been effected by different mechanisms from those associated with changes between TS II and III. During the late phase of sexual development, changes in cortical thickness appear to be primarily mediated by changes in the bone resorption rate (Fig. 4Go). The reasons that support the above conclusion are as follows. First, marrow width was significantly decreased in TS IV girls compared to that in TS III girls and was associated with corresponding decreases in bone resorption markers. Second, the bone resorption markers showed a significant negative correlation with cortical width and a positive correlation with marrow width in TS IV, but not TS II girls. Third, bone resorption markers when corrected for creatinine showed significant negative correlations with bone density measurements in TS III and IV girls, and those girls in the top tertile of BMD exhibited significantly lower bone resorption markers than those in the lower tertile of BMD. However, the correlation between bone density and bone resorption markers failed to maintain significance when bone resorption values were not corrected for creatinine. This apparent discrepancy reminds us of the known limitation of bone resorption markers to predict bone density changes. However, a number of studies have implicated an important role for reduced remodeling in increasing bone gain during puberty. For example, Slemenda et al. (9) have recently shown that black children accumulated 10% greater bone mass than white children and had significantly reduced bone turnover, as measured by serum levels of osteocalcin and tartrate-resistant acid phosphatase, compared to white children during pubertal growth. Although these data provide strong evidence that reduced rates of bone turnover play a major role in accretion of bone mass during puberty in both blacks and whites, determining the extent to which reduced rates of skeletal remodeling contribute to bone gain during this phase requires further longitudinal studies.

The molecular cues that signal down-regulation of skeletal remodeling during the period of sexual maturation can only be speculated upon at this time. Our findings together with other published observations provide evidence for a role for IL-6 in mediating the reduced bone resorption seen during puberty (13, 39). A number of studies have shown that IL-6 is an important regulator of osteoclast cell recruitment and activity (11, 12, 13, 40). In addition, it has been shown that treatment of osteoblasts with sex hormones inhibits the production of IL-6 (13, 41). Consistent with these data, we have found that serum levels of IL-6 were significantly reduced in TS IV girls compared to those in TS II girls. Furthermore, serum levels of IL-6 correlated negatively to BMC adjusted for BMI in TS III (r = -0.45; P < 0.02) and TS IV (r = -0.37; P < 0.05) girls, and those girls with serum IL-6 levels in the upper tertile had significantly lower BMC than those with levels in the lower tertile. These changes, which are just mirror images of those occurring during the menopause, support the role of IL-6 in mediating rapid changes in bone density (39, 42). Because serum levels do not reflect what is happening at the local level, we cannot rule out the possibility that other cytokines besides IL-6 may be involved in mediating decreased bone resorption during puberty. Further studies are warranted to detail the role of sex hormone-induced inhibition of production of IL-6 and other cytokines in mediating reduced remodeling during puberty.

Our study demonstrates for the first time that in addition to the previously reported increases in serum levels of IGF-I and IGFBP-3 (16, 43), serum levels of stimulatory IGFBP-5 increase significantly in TS III girls compared to TS II girls. Although the significance of the increase in serum levels of IGFBP-5 during puberty is not established, it is known that this binding protein has several unique features, including potentiation of IGF-induced osteoblast cell proliferation via both IGF-dependent and IGF-independent mechanisms (44, 45). In regard to the potential mechanisms, which cause a rapid increase in serum stimulatory IGF system components during puberty, interactions between GH and sex steroids have been proposed to play an important role (7, 14, 15). The findings that GH treatment of GH-deficient subjects causes a rapid increase in circulating IGFBP-5 levels and that GH treatment increases IGFBP-5 expression in rat osteoblasts (46) implicate the increase in GH as being responsible for the increase in IGFBP-5 production. However, the direct effect of sex steroids on IGFBP-5 expression also cannot be ruled out, as sex steroids modulate production of IGF system components in vitro (47, 48). Together these data support the hypothesis that GH and sex steroids and their interaction may play a crucial role in regulating the production of IGF-I and its stimulatory IGFBPs during puberty.

We anticipated serum levels of estradiol to show significant correlation with metacarpal bone indexes during puberty based on a number of findings, including the following: 1) bone mass is significantly increased as a result of estrogen therapy in a man with aromatase deficiency (49); 2) serum bioavailable estrogen levels predict BMD in both men and women (50); and 3) animals lacking functional estrogen receptor exhibit significant skeletal phenotypic changes (51). Although serum levels of estradiol were higher in TS IV girls compared to TS II girls, metacarpal indexes did not show significant correlation with serum levels of estradiol in this study. Because serum levels of estradiol were measured at a single time point in this study, this may have compromised our ability to detect significant correlation between serum levels of estradiol and metacarpal indexes.

In summary, the rapid increase in skeletal mass that occurs during puberty is caused by increases in both longitudinal growth as well as cortical thickness. The increase in cortical thickness may be mediated via both periosteal envelope expansion as well as reduction in marrow width. Our data are consistent with a model (Fig. 4Go) in which a sex steroid hormone-induced increase in the GH-IGF axis leads to an increase in longitudinal growth and periosteal expansion, whereas the sex steroid hormone-induced reduction in bone turnover (via IL-6 and other cytokines) leads to an increase in cortical thickness via decreased marrow width. Further studies are needed to examine the extent to which changes in the GH-IGF axis and IL-6 contribute to skeletal changes that occur during puberty and the molecular signals that regulate these growth factors.


    Acknowledgments
 
The authors are grateful to Saral Amarnani for assistance with patient recruitment and sample collection, to Carolyn Hargrave and Henry Cardozo for technical assistance, and to Dr. J. E. Lee for bone marker measurements.


    Footnotes
 
1 This work was supported in part by grants from the NIH (R01–31062), the V.A., and the Loma Linda University Pediatric Department. Back

Received January 6, 1999.

Revised April 21, 1999.

Accepted May 10, 1999.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Rodan GA, Raisz LG, Bilezikian JP. 1996 Pathophysiology of osteoporosis. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego: Academic Press; 979–990.
  2. Ralston SH. 1997 Osteoporosis. Br Med J. 315:469–472.[Free Full Text]
  3. Johnston CC, Slemenda CW. 1994 Peak bone mass, bone loss and risk of fracture. Osteop Int. 1:S43–S45.
  4. Seeman E, Tsalamandris C, Formica C, Hopper JL, McKay J. 1994 Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. J Bone Miner Res. 9:739–743.[Medline]
  5. Seeman E. 1997 From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res. 12:509–521.[CrossRef][Medline]
  6. Gilsanz V, Roe TF, Mora S, Costin G, Goodman WG. 1991 Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med. 325:1597–1600.[Abstract]
  7. Matkovic V. 1996 Editorial: skeletal development and bone turnover revisited. J Clin Endocrinol Metab. 81:2013–2016.[CrossRef][Medline]
  8. Bonjour JP, and Rizzoli R. 1996 Bone acquisition in adolescence. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 465–476.
  9. Slemenda CW, Peacock M, Hui S, Zhou F, Johnston CC. 1997 Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak bone mass. J Bone Miner Res. 12:676–682.[CrossRef][Medline]
  10. Libanati C, Lee JES, Lois E, Baylink DJ. Bone density accretion during sexual development is inversely related to bone resorption and serum interleukin-6 levels. Proc of the 10th Int Congr of Endocrinol. 1996; 737.
  11. Roodman GD. 1996 Advances in bone biology: the osteoclast. Endocr Rev. 17:308–332.[Abstract]
  12. Suda T, Nakamura I, Jimi E, Takahashi N. 1997 Regulation of osteoclast function [Review]. J Bone Miner Res. 12:869–879.[CrossRef][Medline]
  13. Manolagas SC. 1996 The role of IL-6 type cytokines and their receptors in bone [Review]. Ann NY Acad Sci. 840:194–204.[Abstract/Free Full Text]
  14. Caufriez A. 1997 The pubertal spurt: effects of sex steroids on growth hormone and insulin-like growth factor-I. Eur J Obstet Gynecol Reprod Biol. 71:215–217.[CrossRef][Medline]
  15. Holmes SJ, Shalet SM. 1996 Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res. 45:86–93.[Medline]
  16. Juul A, Dalgaard P, Blum WF, et al. 1995 Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 80:2534–2542.[Abstract]
  17. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor-I (IGF-1) and type 1 IGF receptor (IGF1r). Cell. 75:59–72.[Medline]
  18. Baker J, Liu J-P, Robertson EJ, Efstratiadis A. 1993 Role of insulin-like growth factors in embryonic and postnatal development. Cell. 75:73–82.[CrossRef][Medline]
  19. Rosen CJ, Donahue LR, Hunter SJ. 1994 Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 206:83–102.[Abstract]
  20. Rajaram S, Baylink DJ, Mohan S. 1997 Insulin-like growth factor binding proteins in serum and other body fluids: regulation and functions. Endocr Rev. 18:801–831.[Abstract/Free Full Text]
  21. Mohan S, Baylink DJ. 1999 IGF system components and their role in bone metabolism. In: Rosenfeld RG, Roberts CT, eds. IGFs in health and disease. Towton: Humana Press; 457–516.
  22. Gruelich WW, Pyle SI. 1959 Radiographic atlas of skeletal development of the hand and wrist. Palo Alto: Stanford University Press.
  23. Spencer RP, Sagel SS, Garn SM. 1968 Age changes in five parameters of metacarpal growth. Invest Radiol. 3:27–34.[CrossRef][Medline]
  24. Katzman DK, Bachrach LK, Carter DR, Marcus R. 1991 Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab. 73:1332–1339.[Abstract]
  25. Akesson K, Lau K-HW, Johnston P, Imperio E, Baylink DJ. 1998 Effects of short-term calcium depletion and repletion on biochemical markers of bone turnover in young and adult women. J Clin Endocrinol Metab. 83:1921–1927.[Abstract/Free Full Text]
  26. Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink DJ. 1996 Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab. 81:542–546.[Abstract]
  27. Mohan S, Baylink DJ. 1995 Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation. J Clin Endocrinol Metab. 80:637–647.[Abstract]
  28. Nakao Y, Hilliker S, Baylink DJ, Mohan S. 1994 Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro. J Bone Miner Res. 9:865–872.[Medline]
  29. Mohan S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ. 1995 Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab. 80:2638–2645.[Abstract]
  30. Mauras N, Doi SQ, Shapiro JR. 1996 Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans. J Clin Endocrinol Metab. 81:2222–2226.[Abstract]
  31. Blumsohn A, Hannon RA, Wrater R, Barton J, Al-Dejao AW, Eastel R. 1998 Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf). 40:663–670.
  32. Mohan S, and Baylink DJ. 1991 Bone growth factors [Review]. Clin Orthop Rel Res. 30–48.
  33. Won W, and Powell-Braxton L. 1998 Insulin-like growth factor gene targeting. In: Takano K, Hizuka N, Takahashi S-I, eds. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science; 57–63.
  34. Bachrach LK, Marcus R, Ott SM, et al. 1998 Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res. 13:415–421.[CrossRef][Medline]
  35. Spencer EM, Liu CC, Si ECC, Howard GA. 1991 In vivo actions of insulin-like growth factor I on bone formation and resorption in rats. Bone. 12:21–26.[Medline]
  36. Machwate M, Zerath E, Holy X, Pastoureau P, Marie PJ. 1994 Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology. 134:1031–1038.[Abstract]
  37. Bagi CM, DeLeon E, Brommage R, Rosen D, Sommer A. 1995 Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Calcif Tissue Int. 57:40–46.[CrossRef][Medline]
  38. Saban J, Schneider GB, Bolt D, King D. 1996 Erythroid-specific expression of human growth hormone affects bone morphology in transgenic mice. Bone. 18:47–52.[Medline]
  39. Cheleuitte D, Mizuno S, Glowacki J. 1998 In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab. 83:2043–2051.[Abstract/Free Full Text]
  40. Goldring SR, Goldring MB. 1996 Cytokines and skeletal physiology. Clin Orthop Rel Res. 324:13–23.
  41. Manolagas SC, Jilka RL. 1995 Bone marrow, cytokines and bone remodeling. N Engl J Med. 332:305–311.[Free Full Text]
  42. Pacifici R. 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 11:1043–1051.[Medline]
  43. Argente J, Barrios V, Pozo J, Munoz MT, Hervas F, Stene M, Hernandez M. 1993 Normative data for insulin-like growth factors (IGFs), IGF binding proteins, and growth hormone binding protein in a healthy Spanish pediatric population: age- and sex-related changes. J Clin Endocrinol Metab. 77:1522–1528.[Abstract]
  44. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ. 1995 Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 270:20424–20431.[Abstract/Free Full Text]
  45. Mohan S, and Baylink DJ. 1996 Editorial: insulin-like growth (IGF)-binding proteins in serum: do they have additional roles besides modulating the endocrine IGF actions? J Clin Endocrinol Metab. 81:3817–3820.[Free Full Text]
  46. McCarthy TL, Casinghino S, Centrella M, Canalis E. 1994 Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone and the insulin-like growth factors. J Cell Physiol. 160:163–175.[CrossRef][Medline]
  47. Gray TK, Mohan S, Linkhart TA, Baylink DJ. 1989 Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell line, UMR106. Biochem Biophys Res Commun. 158:407–412.[CrossRef][Medline]
  48. Yoshizawa A, Clemmons DR. IGF binding protein-5 synthesis is regulated by testosterone through gene transcriptional mechanisms in androgen responsive human fibroblasts. Proc of the 80th Annual Meet of The Endocrine Soc. 1998; 314.
  49. Bilezikian JP, Morishima A, Bell J, Grumbach MM. 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 339:599–603.[Free Full Text]
  50. Khosla S, Melton JL, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 83:2266–2274.[Abstract/Free Full Text]
  51. Korach KS. 1994 Insights from the study of animals lacking functional estrogen receptor. Science. 266:1524–1527.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Nutr.Home page
F. F. Bezerra, G. M. K. Cabello, L. M. C. Mendonca, and C. M. Donangelo
Bone Mass and Breast Milk Calcium Concentration Are Associated with Vitamin D Receptor Gene Polymorphisms in Adolescent Mothers
J. Nutr., February 1, 2008; 138(2): 277 - 281.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. Leger, I. Mercat, C. Alberti, D. Chevenne, P. Armoogum, J. Tichet, and P. Czernichow
The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children
Eur. J. Endocrinol., November 1, 2007; 157(5): 685 - 692.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
K. E. Govoni, S. K. Lee, Y.-S. Chung, R. R. Behringer, J. E. Wergedal, D. J. Baylink, and S. Mohan
Disruption of insulin-like growth factor-I expression in type II{alpha}I collagen-expressing cells reduces bone length and width in mice
Physiol Genomics, August 20, 2007; 30(3): 354 - 362.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Zhao, D.-H. Xiong, Y. Guo, T.-L. Yang, R. R. Recker, and H.-W. Deng
Polymorphism in the insulin-like growth factor 1 gene is associated with age at menarche in caucasian females
Hum. Reprod., June 1, 2007; 22(6): 1789 - 1794.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
S. Mohan
Riddle of Estrogen Regulation of IGF-I Action and Periosteal Bone Formation
IBMS BoneKEy, February 1, 2006; 3(2): 17 - 19.
[Full Text] [PDF]


Home page
J EndocrinolHome page
S Mohan and D J Baylink
Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences
J. Endocrinol., June 1, 2005; 185(3): 415 - 420.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
R. Eastell
Role of oestrogen in the regulation of bone turnover at the menarche
J. Endocrinol., May 1, 2005; 185(2): 223 - 234.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Endocr. Rev., February 1, 2005; 26(1): 114 - 146.
[Abstract] [Full Text] [PDF]


Home page
The Journal of Early AdolescenceHome page
K. E. Schmitz, M. F. Hovell, J. F. Nichols, V. L. Irvin, K. Keating, G. M. Simon, C. Gehrman, and K. L. Jones
A Validation Study of Early Adolescents' Pubertal Self-Assessments
The Journal of Early Adolescence, November 1, 2004; 24(4): 357 - 384.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Q. Wang, P. H. F. Nicholson, M. Suuriniemi, A. Lyytikainen, E. Helkala, M. Alen, H. Suominen, and S. Cheng
Relationship of Sex Hormones to Bone Geometric Properties and Mineral Density in Early Pubertal Girls
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1698 - 1703.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Kasukawa, D. J. Baylink, J. E. Wergedal, Y. Amaar, A. K. Srivastava, R. Guo, and S. Mohan
Lack of Insulin-Like Growth Factor I Exaggerates the Effect of Calcium Deficiency on Bone Accretion in Mice
Endocrinology, November 1, 2003; 144(11): 4682 - 4689.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Kasukawa, D. J. Baylink, R. Guo, and S. Mohan
Evidence that Sensitivity to Growth Hormone (GH) Is Growth Period and Tissue Type Dependent: Studies in GH-Deficient lit/lit Mice
Endocrinology, September 1, 2003; 144(9): 3950 - 3957.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Mohan, C. Richman, R. Guo, Y. Amaar, L. R. Donahue, J. Wergedal, and D. J. Baylink
Insulin-Like Growth Factor Regulates Peak Bone Mineral Density in Mice by Both Growth Hormone-Dependent and -Independent Mechanisms
Endocrinology, March 1, 2003; 144(3): 929 - 936.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
R. E Black, S. M Williams, I. E Jones, and A. Goulding
Children who avoid drinking cow milk have low dietary calcium intakes and poor bone health
Am. J. Clinical Nutrition, September 1, 2002; 76(3): 675 - 680.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
K J MacKelvie, K M Khan, H A McKay, and C Sanborn
Is there a critical period for bone response to weight-bearing exercise in children and adolescents? a systematic review * Commentary
Br. J. Sports Med., August 1, 2002; 36(4): 250 - 257.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers
Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline
Clin. Chem., February 1, 2002; 48(2): 220 - 235.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow